A carregar...
A single arm phase 1b study of everolimus and sunitinib in patients with advanced renal cell carcinoma (RCC)
BACKGROUND: Everolimus ,an oral inhibitor of mammalian target of rapamycin (mTOR), and sunitinib, an oral inhibitor of VEGF/PDGF receptor tyrosine kinase signaling, have both been shown to provide clinical benefit in patients with advanced RCC. We sought to determine the safety and efficacy of combi...
Na minha lista:
| Publicado no: | Clin Genitourin Cancer |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4754968/ https://ncbi.nlm.nih.gov/pubmed/26174223 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2014.12.011 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|